There is no holding back Gilead Sciences’ (GILD – Analyst Report) hepatitis C virus (HCV) drug Sovaldi. The drug continued its exceptional performance in the second quarter of 2014, helping the company to beat the Consensus Estimate in Q2 on both revenues and earnings. The biopharmaceutical company’s second quarter adjusted earnings (including stock based compensation…
Range Resources RRC reported first-quarter results Thursday. Quarterly production came in at 876 MMcfe per day, up 4% sequentially and 34% year over year and above both the company’s guidance and our forecast of 839 MMcfe/d. Growth was led by Range’s Marcellus acreage, where the firm continued to deliver impressive results across both its liquids-rich…
Biogen Idec (BIIB) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. While oral multiple sclerosis (MS) drug, Tecfidera contributed significantly to revenues, the company also benefited from the approval of an agreement…
Alkermes (NASDAQ ALKS) is leaving no stone unturned to develop its pipeline successfully. The biopharmaceutical company’s pipeline expanded significantly following the purchase of the erstwhile Elan’s drug delivery unit. Elan was acquired by Perrigo Company (NASDAQ PRGO) last year. Important pipeline candidates at Alkermes include ALKS 5461 for treating patients suffering from major depressive disorder…
On Monday morning, it was announced that Avago Technologies (AVGO), a leader in advanced optical, analog and mixed-signal chip design, will acquire LSI Corp (LSI), a strong market participant in hard disk drive semiconductor, system-level silicon for communications and server applications and flash storage solutions. AVGO will pay $6.6 billion for LSI, or $11.15 per…
ARM Holdings reported 3Q13 results on Thursday that were above consensus estimates. On a positive note, ARMH’s license revenue continues to significantly exceed expectations, and ARM PD (Processor Division) royalty revenue continues to outperform ARM’s served available market (SAM) according to management’s guidance. Admittedly, shares are richly valued, and the market clearly wanted a perfect…
